References
1. The pandemic’s impact on the pediatric cancer research landscape.
2020. (Accessed April 28, 2020, at
http://solvingkidscancer.org/covid19webinar/.)
2. Hunger SP, Mullighan CG. Acute Lymphoblastic Leukemia in Children. N
Engl J Med 2015;373:1541-52.
3. Cancer Facts & Figures 2020. American Cancer Society. at
https://www.cancer.org/cancer/cancer-in-children/key-statistics.html#references.)
4. Yeh JM, Ward ZJ, Chaudhry A, et al. Life Expectancy of Adult
Survivors of Childhood Cancer Over 3 Decades. JAMA Oncol 2020.
5. Coronavirus disease (COVID-19) situation reports. 2020. at
https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports.)
6. Van de Haar J, Hoes LR, Coles CE, et al. Caring for patients with
cancer in the COVID-19 era. Nat Medicine 2020.
7. COVID-19: Open letter to cancer researchers. 2020. (Accessed April 6,
2020, at
https://www.cancerresearchuk.org/funding-for-researchers/research-features/2020-04-06-covid-19-open-letter-to-cancer-researchers?utm_source=proactivestatement&utm_campaign=rbc_covid19_researcheropenletter.)
8. Cancer Research UK response to government’s charity package. 2020.
(Accessed April 8, 2020, at
https://www.cancerresearchuk.org/about-us/cancer-news/press-release/2020-04-08-cancer-research-uk-response-to-governments-charity-package.)
9. Excellence NIfHaC. COVID-19 rapid guideline: children and young
people who are immunocompromised May 1, 2020.
10. Dong Y, Mo X, Hu Y, et al. Epidemiological Characteristics of 2143
Pediatric Patients With 2019 Coronavirus Disease in China. Pediatrics
2020.
11. Severe Outcomes Among Patients with Coronavirus Disease 2019
(COVID-19) — United States, February 12–March 16, 2020. MMWR Morb
Mortal Wkly Rep 39:343-6.
12. Guan WJ, Liang WH, Zhao Y, et al. Comorbidity and its impact on 1590
patients with Covid-19 in China: A Nationwide Analysis. Eur Respir J
2020.
13. Preliminary Estimates of the Prevalence of Selected Underlying
Health Conditions Among Patients with Coronavirus Disease 2019 —
United States, February 12–March 28, 2020. MMWR Morb Mortal Wkly
Rep;69:382-6.
14. Coronavirus Disease 2019 in Children - United States, February
12-April 2, 2020. MMWR Morb Mortal Wkly Rep;69:422-6.
15. Liu Y, Yan LM, wan L, et al. Viral dynamics in mild and severe cases
of COVID-19. Lancet Infect Dis 2020.
16. Wang H, Zhang L. Risk of COVID-19 for patients with cancer. Lancet
Oncol 2020.
17. Thevarajan I, Nguyen THO, Koutsakos M, et al. Breadth of concomitant
immune responses prior to patient recovery: a case report of non-severe
COVID-19. Nature Medicine 2020.
18. Qin C, Zhou L, Hu Z, et al. Dysregulation of immune response in
patients with COVID-19 in Wuhan, China. Clin Infect Dis 2020.
19. Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine
storm syndromes and immunosuppression. Lancet 2020;395:1033-4.
20. Mejias A, Dimo B, Suarez NM, et al. Whole blood gene expression
profiles to assess pathogenesis and disease severity in infants with
respiratory syncytial virus infection. PLoS Med 2013;10:e1001549.
21. Garcia-Salido A. Three hypotheses about children COVID19. Pediatr
Infect Dis J 2020.
22. PICS statement regarding novel presentation of multi-system
inflammatory disease. 2020. (Accessed April 27, 2020, at
https://picsociety.uk/news/pics-statement-regarding-novel-presentation-of-multi-system-inflammatory-disease/.)
23. Jones VG, Mills M, Suarez D, et al. COVID-19 and Kawasaki Disease:
Novel Virus and Novel Case. Hosp Pediatr 2020.
24. Turnier JL, Anderson MS, Heizer HR, Jone PN, Glode MP, Dominguez SR.
Concurrent Respiratory Viruses and Kawasaki Disease. Pediatrics
2015;136:e609-14.
25. Kam KQ, Yung CF, Cui L, et al. A Well Infant with Coronavirus
Disease 2019 (COVID-19) with High Viral Load. Clin Infect Dis 2020.
26. Xu Y, Li X, Zhu B, et al. Characteristics of pediatric SARS-CoV-2
infection and potential evidence for persistent fecal viral shedding.
Nature Medicine 2020.
27. Kollmann TR, Levy O, Montgomery RR, Goriely S. Innate immune
function by Toll-like receptors: distinct responses in newborns and the
elderly. Immunity 2012;37:771-83.
28. van den Broek T, Borghans JAM, van Wijk F. The full spectrum of
human naive T cells. Nat Rev Immunol 2018;18:363-73.
29. Prendergast AJ, Klenerman P, Goulder PJ. The impact of differential
antiviral immunity in children and adults. Nat Rev Immunol
2012;12:636-48.
30. McNab F, Mayer-Barber K, Sher A, Wack A, O’Garra A. Type I
interferons in infectious disease. Nat Rev Immunol 2015;15:87-103.
31. Gonzalez-Navajas JM, Lee J, David M, Raz E. Immunomodulatory
functions of type I interferons. Nat Rev Immunol 2012;12:125-35.
32. Hadjadj J, Yatim N, Barnabei L, et al. Impaired type I interferon
activity and exacerbated inflammatory response to in severe COVID-19
patients. MedRxiv 2020.
33. Trouillet-Assant S, Viel S, Gaymard A, et al. Type I IFN
immunoprofiling in COVID-19 patients. J Allergy Clin Immunol 2020.
34. Heinonen S, Velazquez VM, Ye F, et al. Immune profiles provide
insights into respiratory syncytial virus disease severity in young
children. Sci Transl Med 2020;12.
35. Tay MZ, Poh CM, Renia L, MacAry PA, Ng LFP. The trinity of COVID-19:
immunity, inflammation and intervention. Nat Rev Immunol 2020.
36. Goldszmid RS, Dzutsev A, Trinchieri G. Host immune response to
infection and cancer: unexpected commonalities. Cell Host Microbe
2014;15:295-305.
37. Elinav E, Nowarski R, Thaiss CA, Hu B, Jin C, Flavell RA.
Inflammation-induced cancer: crosstalk between tumours, immune cells and
microorganisms. Nat Rev Cancer 2013;13:759-71.
38. Zitvogel L, Galluzzi L, Kepp O, Smyth MJ, Kroemer G. Type I
interferons in anticancer immunity. Nat Rev Immunol 2015;15:405-14.
39. Galluzzi L, Buque A, Kepp O, Zitvogel L, Kroemer G. Immunogenic cell
death in cancer and infectious disease. Nat Rev Immunol 2017;17:97-111.
40. Multhoff G, Molls M, Radons J. Chronic inflammation in cancer
development. Front Immunol 2011;2:98.
41. Thorsson V, Gibbs DL, Brown SD, et al. The Immune Landscape of
Cancer. Immunity 2018;48:812-30 e14.
42. Schultz KR, Carroll A, Heerema NA, et al. Long-term follow-up of
imatinib in pediatric Philadelphia chromosome-positive acute
lymphoblastic leukemia: Children’s Oncology Group study AALL0031.
Leukemia 2014;28:1467-71.
43. Sisk JM, Frieman MB, Machamer CE. Coronavirus S protein-induced
fusion is blocked prior to hemifusion by Abl kinase inhibitors. J Gen
Virol 2018;99:619-30.
44. Martin PJ. How I treat steroid-refractory acute graft-versus-host
disease. Blood 2020.
45. Neelapu SS, Tummala S, Kebriaei P, et al. Toxicity management after
chimeric antigen receptor T cell therapy: one size does not fit ’ALL’.
Nat Rev Clin Oncol 2018;15:218.
46. Snell LM, McGaha TL, Brooks DG. Type I Interferon in Chronic Virus
Infection and Cancer. Trends Immunol 2017;38:542-57.
47. Martinez MA. Compounds with Therapeutic Potential against Novel
Respiratory 2019 Coronavirus. Antimicrob Agents Chemother 2020;64.
48. Gold JA, Wong KK, Szablewki CM, et al. Characteristics and Clinical
Outcomes of Adult Patients Hospitalized with COVID-19 — Georgia, March
2020. MMWR Morb Mortal Wkly Rep.
49. IFS Deaton Review: Are some ethnic groups more vulnerable to
COVID-19 than others? Institute for Fiscal Studies, 2020. at
https://www.ifs.org.uk/inequality/chapter/are-some-ethnic-groups-more-vulnerable-to-covid-19-than-others/.)
50. Francis SS, Wallace AD, Wendt GA, et al. In utero cytomegalovirus
infection and development of childhood acute lymphoblastic leukemia.
Blood 2017;129:1680-4.